Prescriber, operator, purchaser, payer and patient — separate incentives — stress urinary incontinence

1. Summary

The domain dossier flags this section as entirely unsearched, naming five parties it expects to have divergent interests — prescriber, operator, purchaser, payer, and patient — without evidencing any of them. This report finds a concrete, sourced split for two of those roles: under Medicare's own DMEPOS rule, the "treating practitioner" authorized to write the order a home stimulator needs is defined as a physician, physician assistant, nurse practitioner, or clinical nurse specialist — not a physical therapist, the clinician who most often has hands-on contact with a woman doing pelvic floor work [1]. The device category itself is defined by its own federal classification as something "the user" — the patient — inserts and removes, collapsing the usual operator/patient distinction that separates this domain from other DME categories [3]. One manufacturer, Elidah, Inc., has built its ELITONE product around that same split: the device is sold direct-to-consumer without a prescription, while Medicare reimbursement runs through a separate track that the company's own site says requires a prescription and a prior pelvic-floor-exercise trial [4][5]. HCPCS E0740 itself carries no face-to-face-encounter or prior-authorization requirement on CMS's own compliance-program listing, which is a comparatively light procedural bar for the payer to impose relative to what the manufacturer describes about the substantive coverage precondition [2]. None of the five parties' incentives are established beyond what these single sources show, and the pelvic-floor physical therapy practice's own revenue exposure — the dossier's own open question — remains unevidenced below.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Prescriber / ordering practitioner — who is authorized to write the order, and who is not

Medicare's own DMEPOS scope-and-conditions regulation defines, for purposes of ordering durable medical equipment, a "treating practitioner" as "physician as defined in section 1861(r)(1) of the Act, or physician assistant, nurse practitioner, or clinical nurse specialist, as those terms are defined in section 1861(aa)(5) of the Act" [1] [single-source]. The same section defines a "Written Order/Prescription" as "a written communication from a treating practitioner that documents the need for a beneficiary to be provided an item of DMEPOS" [1] [single-source]. Read plainly, a pelvic floor physical therapist — the clinician most likely to be supervising a woman's conservative treatment in person — is not among the practitioner types this definition names, so an order for a DME-billed home stimulator has to originate with, or be co-signed by, a physician, PA, NP, or clinical nurse specialist rather than the PT directly. This is a registry-level reading of the rule's own text, not a claim about how often that hand-off actually happens in practice, which no source located this pass addresses.

Operator — the same person as the patient, by the device's own classification text

21 CFR 876.5320, the classification regulation for this domain's non-implanted electrical continence device, identifies the device as electrodes on "a plug or a pessary" connected to a battery-powered pulse source, inserted "into the rectum or into the vagina," and states "When necessary, the plug or pessary may be removed by the user" [3] [single-source]. The regulation's own vocabulary is "the user," not "the clinician" or "the caregiver," which is the one piece of primary-source text located this pass that speaks directly to who physically operates the device once it is obtained — the patient herself, self-inserting and self-removing at home, rather than a device administered on her by someone else in a clinical setting.

Purchaser — two channels, structured around two different regulatory paths

Elidah, Inc.'s own FAQ page for ELITONE (K183585) states plainly: "Elitone® is FDA-cleared for use without a prescription" for a direct purchase, while separately stating that "coverage requires a prescription and a prerequisite of at least 4-weeks of attempted pelvic floor muscle exercises" for anyone seeking Medicare reimbursement [4] [manufacturer]. The device's own FDA 510(k) summary Indications for Use — "ELITONE is a non-implanted muscle stimulator designed to treat stress urinary incontinence in women. It applies stimulation to the pelvic floor muscles and surrounding tissues" — does not itself state a prescription or over-the-counter designation either way [6] [single-source]; the without-a-prescription characterization above is the manufacturer's own, not independently confirmed against the cleared summary's own prescription-use language this pass. The product page lists three direct-purchase configurations — "Essential Kit" at a listed $429, discounted to $389; a "Bundle" at $539, discounted to $499; and an "Original v1" at $399, discounted to $359 — plus a financing option starting at $36 per month, all described as one-time purchases with free shipping and a 60-day money-back guarantee [5] [manufacturer]. Read together, this is one manufacturer building two purchaser paths onto the same cleared device: a cash buyer who pays the full listed price directly and never needs an order under §1's definition, and a Medicare-reimbursement buyer who does. No comparable direct-purchase or pricing information for InTone/InToneMV (InControl Medical) or InWave (Zynex Medical) was retrieved this pass — see §5.

Payer — a light procedural bar on top of a substantive coverage precondition

CMS's own DMEPOS Master List compliance-program page for HCPCS E0740 states "Prior Authorization Required? No" and "F2F and Written Order Prior to Delivery? No" [2] [single-source]. That page addresses only the ordering and authorization procedure, not medical-necessity criteria, and it sits alongside — not instead of — the substantive four-week pelvic-floor-exercise precondition that the manufacturer's own FAQ describes for reimbursement [4] [manufacturer]. On the sources retrieved this pass, the payer's administrative bar for this specific code is low (no mandatory face-to-face visit or prior authorization filing) while the clinical precondition manufacturers themselves describe to prospective buyers is not; this report does not independently confirm the four-week precondition against CMS's own coverage text, which is this domain's reimbursement report's territory.

Patient — the party bearing both the operating burden and, on the evidence above, the channel choice

No source located this pass separately evidences patient-specific financial exposure (coinsurance, deductible) or a patient-reported reason for choosing the cash channel over the Medicare channel or vice versa. What is established above is structural rather than experiential: the same person who must self-administer the device under 21 CFR 876.5320's own wording [3] is also the party who, per one manufacturer's own site, decides which of two purchase paths to take and absorbs whichever precondition — full cash price or a documented conservative-therapy trial — that path requires [4][5] [manufacturer].

4. Sources

[1] Durable medical equipment, prosthetics, orthotics and supplies (DMEPOS): Scope and conditions — eCFR, Title 42 (issue 2026-08-13; accessed 2026-09-01). 42 CFR 410.38 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-410/subpart-B/section-410.38 [federal-registry] [2] HCPCS Code E0740 — Master List of DMEPOS Items Potentially Subject to Conditions of Payment — Centers for Medicare & Medicaid Services (page undated; accessed 2026-09-01). HCPCS E0740 — https://www.cms.gov/data-research/monitoring-programs/medicare-fee-service-compliance-programs/medical-review-and-education/master-list-dmepos-items-potentially-subject-conditions-payment/e0740 [payer-policy] [3] Nonimplanted electrical continence device — eCFR, Title 21 (issue 2026-08-31; accessed 2026-09-01). 21 CFR 876.5320 — https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-876/subpart-F/section-876.5320 [federal-registry] [4] Frequently Asked Questions — Elidah, Inc. (page undated; accessed 2026-09-01). Priced device cleared as K183585 — https://elitone.com/faqs/ [manufacturer] [5] ELITONE product page — Elidah, Inc. (page undated; accessed 2026-09-01). K183585 — https://elitone.com/product/elitone/ [manufacturer] [6] FDA 510(k) summary K183585 — Elitone Device, Elidah, Inc. (decision 2019-02-11; accessed 2026-09-01). K183585 — https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183585.pdf [federal-registry]

5. Sourcing & Gaps

Well established: Nothing in this report rests on two independent, non-affiliated primary sources; every substantive line is single-source or manufacturer-marked, per the sourcing_summary above, and is presented that way in §3 rather than stated plainly.

Thin: The ordering-practitioner definition [1], the device's self-operated classification text [3], the 510(k) summary's silence on prescription status [6], and CMS's own no-F2F/no-prior- authorization statement for E0740 [2] are each a single federal registry or agency source. Elidah, Inc.'s statements about its own prescription-free purchase channel, its Medicare-reimbursement precondition, and its pricing [4][5] are manufacturer-marked throughout and describe only one company's own product and business practice, not the category.

Rescoped from class 3: None new in this report. The dossier's own open question about whether clinicians "would" prescribe a home device and bill accordingly is a class-3 question the dossier already declines to answer (§9); this report does not re-raise it and instead documents the registry-level fact of who is authorized to write the order [1], which is the closest answerable neighbor to that question found this pass.

Out of scope: The full text of NCD 230.8 and any DMEPOS payment-rate document, both already this domain's reimbursement section's territory; CPT-coded PT and biofeedback visit billing (97110/97112 and 90911-descendant code families), AMA-licensed and named here only by family, not descriptor; veterinary and non-US/non-EU material, per this repo's standing exclusions.

Not searched vs. not found: Not found, attempted: a readable version of CMS Program Memorandum AB-01-79 (a 2001 transmittal on biofeedback coverage for incontinence, found by search and fetched) — the retrieved PDF did not extract as legible text, so nothing from it is cited above, consistent with this domain's care-pathway report's identical experience with a different CMS PDF. Not retrieved, blocked: InControl Medical's own site (incontrolmedical.com, including its FAQ page) and Zynex Medical's InWave brochure (redirected to altiveramedical.com) each returned HTTP 403 to direct fetch, so no independent purchase-channel or pricing comparison to ELITONE's was possible for either competing device; this mirrors the domain dossier's own note that InControl Medical's pricing page returned HTTP 403 five days earlier. Not searched: patient out-of-pocket coinsurance or deductible exposure specifically for E0740; state-level scope-of-practice rules on whether a physical therapist can independently order DME in any state; any survey or interview-based account of why a given patient chose the cash channel over the insurance channel, which would in any case be a class-3 question about a choice already made rather than one still to be made, and so would need its own revealed-behaviour framing before it could be researched.

[inference] None in this report. Every substantive line in §3 restates what a retrieved source itself says; no synthesis beyond that restatement was written into Details.

6. Claim Candidates